Stock · NSE
ZYDUSLIFE 1,036.45 ▼ 4.40 (-0.42%) Last 2 days · 15m candles 26/5/2026, 19:14:11
Open: 1,047.10 High: 1,047.10 Low: 1,030.60 Prev: 1,040.85
News mentioning ZYDUSLIFE VERIFIED ET Stocks · 2d ★ ON YOUR LIST ☆
6 pharma stocks that Bernstein sees up to 40% upside potential. Do you own any? AI summary · POSITIVE
· Bernstein initiated coverage on six pharmaceutical stocks. · The brokerage cited AI, innovation, and a strengthening ecosystem as drivers for the Indian healthcare sector. · Zydus Lifesciences was named as the top pick with significant upside potential. VERIFIED ET Markets · 2d ★ ON YOUR LIST ☆
6 pharma stocks that Bernstein sees up to 40% upside potential. Do you own any? AI summary · POSITIVE
· Bernstein initiated coverage on six pharmaceutical stocks. · The brokerage cited AI, innovation, and a strengthening ecosystem as drivers for the Indian healthcare sector. · Zydus Lifesciences was named as the top pick with significant upside potential. VERIFIED ET Finance · 2d ★ ON YOUR LIST ☆
Sakar Healthcare partners with Zydus Lifesciences for GCC Markets AI summary · NEUTRAL
· Sakar Healthcare has entered into a partnership with Zydus Lifesciences to supply oncology products in GCC countries and other emerging markets. · This agreement represents Sakar Healthcare's 40th global collaboration in the anti-cancer product segment. · The company is actively pursuing regulatory filings and approvals in highly regulated international markets. VERIFIED ET Markets · 4d ★ ON YOUR LIST ☆
Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sector AI summary · POSITIVE
· Bernstein has initiated coverage on six Indian pharma stocks, naming Zydus Lifesciences as its top pick. · The brokerage identifies AI-led innovation, niche area advancements, and an improved quality culture as key growth drivers for the Indian healthcare sector. · Attractive valuations are also cited as a factor supporting a positive outlook for the industry. VERIFIED ET Stocks · 4d ★ ON YOUR LIST ☆
Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sector AI summary · POSITIVE
· Bernstein has initiated coverage on six Indian pharma stocks, naming Zydus Lifesciences as its top pick. · The brokerage identifies AI-led innovation, niche area advancements, and an improved quality culture as key growth drivers for the Indian healthcare sector. · Attractive valuations are also cited as a factor supporting a positive outlook for the industry. VERIFIED ET Stocks · 6d ★ ON YOUR LIST ☆
Zydus Lifesciences,3 stocks hit 52-week highs, rally up to 25% in a month AI summary · NEUTRAL
· Zydus Lifesciences is among the stocks that have reached a 52-week high. · These stocks have experienced a rally of up to 25% in the past month. · The title does not provide specific details on other stocks or the exact percentage rally for Zydus Lifesciences. Google News, NIFTY/SENSEX · 6d ★ ON YOUR LIST ☆
Mankind Pharma, Zydus Lifesciences fuel Nifty Pharma to 52-week high; index trades 9.8% higher YTD - Upstox Summarize with AI → VERIFIED ET Stocks · 6d ★ ON YOUR LIST ☆
Zydus Lifesciences shares soar 7% to fresh record high after Q4 results. Should you buy, sell or hold? AI summary · POSITIVE
· Zydus Lifesciences shares reached a new 52-week high, increasing by 7%. · The company announced a 9% rise in net profit and over 16% revenue growth for the January-March quarter. · A share buyback program of Rs 1,100 crore was announced. VERIFIED Mint Markets · 6d ★ ON YOUR LIST ☆
Zydus Lifesciences share price jumps over 6% after Q4 results. Should you buy or sell? AI summary · POSITIVE
· Zydus Lifesciences shares increased by over 6% following its Q4 results. · The company reported a 14.6% rise in net profit to ₹1,592.9 crore and revenue of ₹7,587 crore. · The board approved a ₹1,100 crore share buyback and a Re 1 dividend. VERIFIED ET Markets · 6d ★ ON YOUR LIST ☆
Zydus Lifesciences' Rs 1,100 crore share buyback at 13% premium: Check record date, other details AI summary · NEUTRAL
· Zydus Lifesciences announced a share buyback program worth Rs 1,100 crore. · The buyback offers shareholders a premium price, with the record date set for May 29. · The company will conduct the buyback through the tender route. VERIFIED ET Stocks · 6d ★ ON YOUR LIST ☆
Zydus Lifesciences' Rs 1,100 crore share buyback at 13% premium: Check record date, other details AI summary · NEUTRAL
· Zydus Lifesciences announced a share buyback program valued at Rs 1,100 crore. · The record date for determining eligibility for the buyback is May 29. · The buyback will be executed via the tender route, offering shareholders a premium price. Google News, NIFTY/SENSEX · 6d ★ ON YOUR LIST ☆
Sensex Today | Stock Market LIVE Updates: GIFT Nifty trades 200 points lower; Zydus Life in focus - CNBC TV18 Summarize with AI → VERIFIED ET Finance · 7d ★ ON YOUR LIST ☆
Zydus Lifesciences to pursue acquisitions in specialty, rare diseases AI summary · POSITIVE
· Zydus Lifesciences will acquire US firm Assertio Holdings for $166.40 million. · The acquisition aims to establish a strong specialty oncology business in the US. · The company reported robust financial growth for the fourth quarter of 2025-26 and announced a share buyback and dividend. VERIFIED Mint Companies · 7d ★ ON YOUR LIST ☆
Zydus Lifesciences beats estimates, sees high-teens growth in FY27 AI summary · POSITIVE
· Zydus Lifesciences reported FY26 revenue from operations of ₹27,148.4 crore, a 17% increase year-on-year. · Adjusted net profit for FY26 grew 15% to ₹5,456.4 crore. · The company anticipates high-teens growth for FY27. VERIFIED Mint Companies · 7d ★ ON YOUR LIST ☆
Zydus Wellness sees more of price-led growth as costs surge AI summary · NEUTRAL
· Zydus Wellness is shifting its growth strategy due to rising input costs and acquisition-led expansion. · The company may increase its reliance on price-led growth. · This indicates broader economic pressure on consumer-facing firms due to the West Asia war. VERIFIED Mint Markets · 11d ★ ON YOUR LIST ☆
Raja Venkatraman, MarketSmith recommend five stocks for 15 May AI summary · POSITIVE
· The Indian stock market rebounded on May 14, with the Sensex increasing by 790 points. · Analysts recommend buying Nippon Life India Asset Management. · Analysts recommend buying Zydus Lifesciences. VERIFIED ET Stocks · 12d ★ ON YOUR LIST ☆
Market Trading Guide: Buy Zydus Lifesciences, Solar Industries on Friday for gains up to 15% AI summary · POSITIVE
· Nifty 50 closed higher for the second consecutive session, supported by banking, metal, and pharma stocks. · Analysts identified 23,800 as a significant resistance level for the Nifty 50 . · Zydus Lifesciences and Solar Industries India are recommended for potential near-term gains. VERIFIED ET Markets · 12d ★ ON YOUR LIST ☆
Zydus Lifesciences shares jump 6% on buyback buzz; co announces $166 mn Assertio acquisition AI summary · POSITIVE
· Zydus Lifesciences shares increased by 6% following news of a potential share buyback . · The company announced the acquisition of US-based Assertio for $166 million. · The board will meet on May 19 to consider the share buyback proposal. VERIFIED Economic Times News · 12d ★ ON YOUR LIST ☆
Zydus Lifesciences shares surge 6% on buyback buzz AI summary · POSITIVE
· Zydus Lifesciences shares increased by 6% following news of a potential share buyback . · The company's board will convene on May 19 to discuss the share buyback proposal. · Zydus Lifesciences also announced the acquisition of US-based Assertio for $166 million. VERIFIED ET Stocks · 12d ★ ON YOUR LIST ☆
Zydus Lifesciences shares jump 6% on buyback buzz; co announces $166 mn Assertio acquisition AI summary · POSITIVE
· Zydus Lifesciences shares increased by 6% following news of a potential share buyback . · The company's board will convene on May 19 to discuss the share buyback proposal. · Zydus Lifesciences announced the acquisition of US-based Assertio for $166 million. VERIFIED ET Finance · 12d ★ ON YOUR LIST ☆
Zydus to buy Assertio for $166.4 million AI summary · POSITIVE
· Zydus is acquiring US-based Assertio Holdings for $166.40 million. · The acquisition aims to bolster Zydus's specialty oncology presence in the US. · The deal will provide Zydus access to Assertio's commercial platform and its oncology asset, Rolvedon. VERIFIED Mint Markets · 12d ★ ON YOUR LIST ☆
Zydus Lifesciences sets board meeting date to consider buyback of shares. Details here AI summary · NEUTRAL
· Zydus Lifesciences board will meet on May 19 to consider a share buyback . · The meeting will address potential buyback details. · Market participants will monitor the size, pricing, and structure of the proposed buyback . VERIFIED Mint Markets · 12d ★ ON YOUR LIST ☆
Stocks to watch: HAL, IRFC, Bharti Airtel, Zydus Lifesciences among 10 shares in focus today AI summary · NEUTRAL
· The Indian stock market is expected to open higher on Thursday, 14 May. · Gift Nifty trends indicate a continuation of the market's gaining streak. · HAL, IRFC, Bharti Airtel, and Zydus Lifesciences are among the 10 stocks in focus. Google News, India stocks · 12d ★ ON YOUR LIST ☆
Stocks to watch: HAL, IRFC, Bharti Airtel, Zydus Lifesciences among 10 shares in focus today - Mint Summarize with AI → VERIFIED ET Stocks · 12d ★ ON YOUR LIST ☆
Stocks in news: HAL, TMPV, Bharti Airtel, Anant Raj, Zydus Life, Tata Motors AI summary · NEUTRAL
· HAL, Tata Motors, and Bharti Airtel are in focus due to quarterly results and news developments. · Zydus Lifesciences is nearing a US acquisition. · Maruti Suzuki commits to green logistics. VERIFIED ET Markets · 12d ★ ON YOUR LIST ☆
Stocks in news: HAL, TMPV, Bharti Airtel, Anant Raj, Zydus Life, Tata Motors AI summary · NEUTRAL
· HAL, Tata Motors, and Bharti Airtel are in focus due to quarterly results and news developments. · Zydus Lifesciences is nearing a US acquisition. · Maruti Suzuki commits to green logistics. VERIFIED ET Finance · 12d ★ ON YOUR LIST ☆
Zydus Lifesciences acquires US pharma firm Assertio for $166 million AI summary · POSITIVE
· Zydus Lifesciences has acquired US pharma firm Assertio Holdings for $166.40 million. · The acquisition includes Assertio's cancer treatment, Rolvedon. · This move aims to strengthen Zydus' position in the US specialty oncology market. VERIFIED Mint Companies · 13d ★ ON YOUR LIST ☆
Zydus to acquire US cancer drug company Assertio for $166.4 million in all-cash deal AI summary · NEUTRAL
· Zydus Lifesciences will acquire US-based cancer drug company Assertio for $166.4 million. · The transaction will be an all-cash deal. · This acquisition is part of Zydus' strategy to diversify and enhance its specialty offerings in regulated markets. VERIFIED ET Finance · 13d ★ ON YOUR LIST ☆
Zydus Lifesciences close to buying US oncology drug maker for $100 to 150 million: Sources AI summary · NEUTRAL
· Zydus Lifesciences is nearing a deal to acquire a US-based oncology drug maker. · The potential acquisition is valued between $100 million and $150 million. · The move aims to establish Zydus's distribution network for anti-cancer drugs in the US and includes the target's biologic drug pipeline.